BTCC
/
BTCC Square
/
Global Cryptocurrency
/
BioNTech Shares Rise on Regulatory Win and Analyst Upgrade
BioNTech Shares Rise on Regulatory Win and Analyst Upgrade
6
2
BTCCSquare news:
BioNTech's stock climbed nearly 3% Monday, outpacing the S&P 500's modest gains, after a CDC advisory panel rejected prescription requirements for COVID vaccines and J.P. Morgan raised its price target. The German biotech—famed for co-developing Pfizer's Comirnaty jab—benefited from regulatory tailwinds as healthcare authorities weigh broader vaccine access.
While the panel recommended patient consultations for COVID shots, its non-binding vote against mandatory prescriptions relieved vaccine makers. Analyst Jessica Fye's model revisions reflected growing confidence in BioNTech's pipeline beyond pandemic-era products, though Comirnaty remains central to its valuation.
By:
